Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments

INTRODUCTION: Randomised controlled trials have shown that targeted therapies like sunitinib are effective in metastatic renal cell carcinoma (mRCC). Little is known about the current use of these therapies, and their associated costs and effects in daily clinical practice. We estimated the real-wor...

Descripción completa

Detalles Bibliográficos
Autores principales: De Groot, S., Blommestein, H. M., Redekop, W. K., Sleijfer, S., Kiemeney, L. A. L. M., Oosterwijk, E., Uyl-de Groot, C. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5439671/
https://www.ncbi.nlm.nih.gov/pubmed/28531203
http://dx.doi.org/10.1371/journal.pone.0177364

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5439671/
https://www.ncbi.nlm.nih.gov/pubmed/28531203
http://dx.doi.org/10.1371/journal.pone.0177364

Ejemplares similares